.jetcityimage/iStock Editorial through Getty Images Morgan Stanley has actually picked Eli Lilly (NYSE: LLY) as its leading biopharma selection for 2025 as well as rated another 9 names in the space as over weight. The expenditure financial institution said in a note that it continues to feel “diabesity is actually readied to come to be.